Kyle Horlen
Papers
7
Total Citations
107
H-Index
2
About
Kyle Horlen is a pioneering researcher in the field of oral biotherapeutic delivery, focusing on the development of an ingestible robotic pill designed to replace painful injections for patients requiring chronic biologic therapies. His major contributions center on demonstrating that this novel platform can safely and reliably deliver large molecules—including antibodies, peptides, and hormones—with bioavailability comparable to traditional subcutaneous or intravenous administration. Horlen’s landmark 2021 study, cited 94 times, established the safety and tolerability of the robotic pill in healthy subjects, marking a critical step toward transforming patient compliance. Subsequent work has shown successful transenteric delivery of antibodies and complex biologics, such as uste kinumab and teriparatide, in both canine models and human Phase 1 trials. His research has also explored patient preference for oral delivery of follicle-stimulating hormone and GLP-1 agonists, underscoring the clinical and quality-of-life benefits of this technology. Horlen’s work, conducted at Rani Therapeutics, represents a paradigm shift in biotherapeutic administration, offering a needle-free future for managing chronic diseases.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7